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Abstract 5-HT1A and 5-HT7 receptor ligands might have
antidepressant-like properties and improve cognitive function.
We previously reported significant antidepressant- and
anxiolytic-like effects of two dual 5-HT1A and 5-HT7 re-
ceptor antagonists in various behavioral tests in rodents.
As a continuation of our previous experiments, in this
study we aimed to investigate whether chronic adminis-
tration of 1-[(2,6-dimethylphenoxy)ethoxyethyl]-4-(2-
methoxyphenyl)piperazine hydrochloride (HBK-14) and
1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-
methoxyphenyl)piperazine hydrochloride (HBK-15)
caused antidepressant-like effects and elevated serotonin
levels in the murine hippocampus. We also evaluated
cholinolytic properties and the influence of acute administra-
tion of both compounds on cognitive function in mice. To
assess antidepressant-like properties and the influence on
learning and memory we used forced swim test and step-
through passive avoidance task in mice, respectively. Both
compounds showed antidepressant-like properties and signif-
icantly elevated serotonin levels in the hippocampus after
chronic treatment (HBK-14 – 2.5 mg/kg; HBK-15 – 0.625
and 1.25 mg/kg). HBK-15 administered chronically
antidepressant-like activity at lower dose (0.625 mg/kg) than
the dose active after acute treatment (1.25 mg/kg). None of the
compounds affected locomotor activity of mice. HBK-15 pos-
sessed very weak cholinolytic properties, whereas HBK-14
did not show any effect on muscarinic receptors. Only
HBK-15 (0.625 mg/kg) presented memory-enhancing proper-
ties and ameliorated cognitive impairments caused by scopol-
amine (1 mg/kg). Our results indicate that 5-HT1A and 5-HT7
antagonists might have potential in the treatment of depression
and possess positive influence on cognitive function.
Keywords 2-methoxyphenylpiperazine derivative . 5-HT1A
receptor antagonist . 5-HT7 receptor antagonist . Forced swim
test . Step-through passive-avoidance test . Mice
Introduction
Major depression affects millions of people worldwide and
contributes to their disability. Besides the well-defined depres-
sive symptoms, patients often report cognitive disturbances,
which significantly deteriorate their functioning. Therefore,
the scientists still search for the new compounds with in-
creased efficacy and positive influence on cognition.
Current antidepressants worsen (e.g. tricyclic antidepres-
sants) or have no influence (e.g. selective serotonin reuptake
inhibitors) on cognitive function (for review see: Biringer et al.
2009). Some Authors suggested that reboxetine, bupropion,
duloxetine or venlafaxine might have more beneficial effect
on cognitive function than other antidepressants. However,
recent meta-analysis of clinical trials showed that only
vortioxetine significantly improved cognition in depressed pa-
tients (McIntyre et al. 2016). Positive influence on cognitive
function was most likely due to the drug’s broad receptor
profile. Studies on animals showed that both 5-HT1A and 5-
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HT7 receptor ligands might enhance cognitive function in ro-
dents (reviewed in Glikmann-Johnston et al. 2015 and
Meneses 2014). Interestingly, 5-HT1A antagonism facilitated
memory retention possibly via 5-HT7 activation, and 5-HT7
receptor could improve emotional memory upon reduced 5-
HT1A receptor transmission (Stiedl et al. 2015).
We previously reported significant antidepressant- and
anxiolytic-like effects of two dual 5-HT1A and 5-HT7 receptor
antagonists in various behavioral tests in rodents
(Waszkielewicz et al. 2015; Pytka et al. 2015a). As a contin-
uation of our previous experiments, in this study we aimed to
investigate whether chronic administration of 1-[(2,6-
dimethylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)
piperazine hydrochloride (HBK-14) and 1-[(2-chloro-6-
methylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine
hydrochloride (HBK-15) caused antidepressant-like effects
and elevated serotonin levels in the murine hippocampus.
We also evaluated cholinolytic properties and the influence




Adult male mice (stock’s name: CD-1, 18–21 g), purchased
from Animal House at the Faculty of Pharmacy, Jagiellonian
University Medical College, Krakow, Poland or and male
guinea-pigs (Outbred CV, 300-400 g), purchased from
Laboratory Animals Husbandry Maria Staniszewska,
Słaboszów, Poland were used in the experiments. The groups
of 15 mice or 2 guinea-pigs were kept to a plastic cage
(60 cm × 38 cm × 20 cm) at a room temperature
(22 ± 2 °C), on 12 h light/dark cycles (the lights turned on at
7:00 a.m., and off at 19:00 p.m.). Animals had free access to
standard laboratory food and tap water. Behavioral experi-
ments were performed between 9 a.m. and 2 p.m. and each
experimental group consisted of 8–10 randomly selected ani-
mals. In acute experiments mice were used only once in each
test. After the experiment mice were killed by cervical dislo-
cation. Guinea-pigs were anaesthetized (37 mg/kg sodium
pentobarbital) and killed by cervical dislocation. All experi-
mental procedures were carried out in accordance with EU
Directive 2010/63/EU and approved by the I Local Ethics
Committee for Experiments on Animals of the Jagiellonian
University in Krakow, Poland (approval numbers: 52/2014
and 102/2015).
Drugs




were synthesized in the Department of Bioorganic
Chemistry, Chair of Organic Chemistry, Pharmaceutical
Faculty, Jagiellonian University (Waszkielewicz et al. 2015).
HBK-14, HBK-15, and scopolamine (Sigma, Germany) were
dissolved in saline, and administered intraperitoneally (i.p.) at
a volume of 10 ml/kg. Carbachol (Sigma, Germany) was dis-
solved in distilled water and used in functional experiments.
Experimental protocol for chronic experiments
After habituation period, mice were injected (i.p.) with HBK-
14 (1.25 or 2.5 mg/kg), HBK-15 (0.3, 0.625 or 1.25 mg/kg),
fluoxetine (10 mg/kg – positive control) or saline (control
groups) for 21 consecutive days (Fig. 2). After that time the
animals were subjected to behavioral tests (i.e. forced swim
test and spontaneous locomotor activity), which were then
followed by tissue collection and biochemical analysis. The
doses of compounds used in this study were based on our
previous experiments (Pytka et al. 2015b; Pytka et al. 2015a).
Forced swim test
Forced swim test was performed according to the method
previously described (Borsini 1995; Pytka et al. 2015c) with
some modifications (Tanaka and Telegdy 2008; Pytka et al.
2015c; Pytka et al. 2016a). Mice were placed individually in
glass cylinders (height 25 cm, diameter 10 cm) containing
10 cm3 of water (23–25 °C), and left there for 6 min. The total
time of immobility, swimming and climbing was recorded
during the final 4 min of the test. The animal was regarded
as: 1) immobile when it was floating passively in the water or
making only small movements to keep its head above the
water surface; 2) climbing when it was making vertical move-
ments against walls; 3) swimming when it was making hori-
zontal movements across the water surface. The experiments
were recorded and scored using aLab.io software by a trained
observer blind to the treatments.
Spontaneous locomotor activity
The locomotor activity was performed as previously described
(Pytka et al. 2015b). Briefly, locomotor activity was recorded
for each animal individually using activity cages, which were
supplied with I.R. horizontal beam emitters (Activity Cage
7441, Ugo Basile, Italy) connected to a counter for the record-
ing of light-beam interruptions. Each mouse was placed in a
cage (40 cm × 40 cm × 31 cm), made of clear Perspex, for a
30 min habituation period. After that time the number of
crossings of photobeams was measured from the 2nd to the
6th min (i.e., the time equal to the observation period in the
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forced swim test). The cages were disinfected with 70% eth-
anol after each mouse.
The evaluation of serotonin level in the hippocampus
Removed hippocampi were rinsed with phosphate-buffered
saline (PBS) to remove excess blood. The tissue was homog-
enized in PBS buffer enriched with 1% stabilizer, included in
the kit, and stored in -80 °C. After two freeze-thaw cycles that
were performed to break the cell membranes, the homoge-
nates were centrifuged for 10 min at 4000 x g. Removed
supernate were aliquoted and stored at -80 °C until analysis.
Aliquots of each sample were taken and serotonin levels
were determined using an ELISA kit from Labor Diagnostyka
Nord GmbH &Co. KG (LDN, Nordhorn, Germany), accord-
ing to the manufacturer’s instructions. The absorbance was
read at 450 nm and the corresponding concentration was de-
termined from the standard curve.
The serotonin level in murine hippocampi was additionally
evaluated after single injection.
The influence on the guinea-pig ileum contraction induced
by carbachol
The experiment was performed according to the method de-
scribed by Mogilski and colleagues (2015). A segment
(15 cm) of male guinea-pig ileum was excised from the small
intestine and immersed into a Krebs solution (NaCl 120 mM,
KCl 5.6 mM, MgCl2 2.2 mM, CaCl2 2.4 mM, NaHCO3
19 mM, glucose 10 mM). The part of the ileum (5 cm) that
was the closest to the ileo-cecal junction was removed. After
2 cm-long fragments of the ileum were cut, each of them was
placed in 20 ml chamber of tissue organ bath system (Tissue
Organ Bath System — 750 TOBS, DMT, Denmark) filled
with the Krebs solution at 37 °C, pH 7.4, with constant oxy-
genation (O2/CO2, 19:1). The segments were stretched by
means of closing clips between the metal rod and the force–
displacement transducer. The preparations were allowed to
stabilize in organ baths for 60 min under a resting tension of
0.5 g and were washed every 15 min with fresh Krebs solu-
tion. After the equilibration period a cumulative concentra-
tion–response curve was constructed for muscarinic receptor
agonist: carbachol (3 nM – 3 μM). Then the tissues were
incubated with one of the concentrations of tested compounds
for 15 min and the next cumulative concentration curve to the
agonist was constructed. Only one concentration of the poten-
tial antagonist was tested in each piece of the tissue. The
experiment was repeated four to eight times.
Step-through passive avoidance task in mice after acute
administration
Step-through passive avoidance task was performed accord-
ing to the method previously described (Lee et al. 2016; Pytka
et al. 2016a). The apparatus for step-through passive avoid-
ance task consisted of two compartments, separated by an
automated sliding door (LE872, Bioseb, France). For acquisi-
tion session, mice were placed individually in an illuminated
white compartment (20 cm × 21 cm× 20 cm, 1000 lx) with the
c l o s e d d o o r t o a sm a l l e r d a r k c omp a r tm e n t
(7.3 cm × 7.5 cm × 14 cm, 10 lx) equipped with an electric
grid floor (stainless steel rods through which an electric
footshock is delivered). After 30 s the door to a smaller com-
partment were opened. Immediately after the mouse entered
the smaller dark compartment, the door closed and the rodent
was punished by an inescapable electric foot shock (0.8 mA
Fig. 2 A schematic diagram of chronic administration of studied
compounds and behavioral testing. HBK-14 (1.25 and 2.5 mg/kg),
HBK-15 (0.3, 0.625 and 1.25 mg/kg), fluoxetine (10 mg/kg) or saline
were administered intraperitoneally to mice for 21 consecutive days.
Control groups received 0.9% NaCl (saline)
Fig. 1 Chemical structures of the studied dual 5-HT1A and 5-HT7
receptor antagonists. a 1-[(2,6-dimethylphenoxy)ethoxyethyl]-4-(2-
methoxyphenyl)piperazine hydrochloride (HBK-14); b 1-[(2-chloro-6-
methylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine
hydrochloride (HBK-15)
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for 2 s). The mice, which did not enter the dark compartment
within 50 s were excluded from the study. On the following
day (24 h later), the pretrained animals were placed again into
the illuminated compartment and observed up to 300 s (reten-
tion session). The experimental procedure was similar to ac-
quisition session, but this timemice did not receive the electric
shock after the entrance to the smaller dark compartment.
Mice, which avoided the dark compartment for 300 s were
considered to remember the task.
Evaluation of cognitive-enhancing properties in naïve mice
HBK-14 (1.25 or 2.5 mg/kg), HBK-15 (0.3, 0.625 or 1.25mg/
kg) or fluoxetine (5, 10, 20 mg/kg) were administered (i.p.)
30 min before acquisition trial. Control groups were injected
(i.p.) with saline. The doses of compounds used in this study
were based on our previous experiments (Pytka et al. 2015b;
Pytka et al. 2015a).
The effect on scopolamine-induced cognitive dysfunction
HBK-14 (1.25 or 2.5 mg/kg), HBK-15 (0.3, 0.625 or 1.25mg/
kg) or fluoxetine (5, 10, 20 mg/kg) and scopolamine (1 mg/
kg) were administered (i.p.) 30min before the acquisition trial.
Control groups were injected (i.p.) with saline. The doses of
the studied compounds and scopolamine were based on our
previous experiments (Pytka et al. 2015b; Pytka et al. 2015a;
Pytka et al. 2016a).
Data analysis
Results are presented as means ± S.E.M. In the forced swim
test, spontaneous locomotor activity, and biochemical studies
comparisons between experimental and control groups were
performed by one-way ANOVA, followed by Newman-Keuls
post hoc, when three or more groups were compared or
Student’s t-test if two groups were compared. In the step-
through passive avoidance task one-way ANOVA followed
by Turkey’s test post hoc was used. A value of p < 0.05 was
considered to be significant.
In functional experiments pKB value was estimated using




Where B was the molar antagonist concentration and DR
was the ratio between the EC50 of the agonist in the presence
and absence of the antagonist. pKB value was equivalent to the
pA2 value and was calculated if only one concentration of
tested compound was effective.
Results
Antidepressant-like activity of studied compounds
and fluoxetine in the forced swim test in mice after chronic
treatment
HBK-14 (2.5 mg/kg) injected for 21 days significantly re-
duced immobility of mice by 21% [F(2,21) = 5.683,
p < 0.05], increased swimming behavior by 67%
[F(2,21) = 4.270, p < 0.05] and had no effect on climbing
[F(2,21) = 3.364, ns] (Fig. 3a).
Chronic treatment with HBK-15 (0.625 and 1.25 mg/kg)
significantly decreased immobility of mice by 19% and 29%
[F(3,28) = 6.929, p < 0.01], respectively (Fig. 3b). The com-
pound administered for 21 days caused an increase in swim-
ming behavior by 75% at the dose 0.625 mg/kg and by 111%
at the dose 1.25 mg/kg [F(3,28) = 6.558, p < 0.01]. HBK-15
had no significant influence on climbing [F(3,28) = 0.356, ns].
Fluoxetine (10 mg/kg) administered for 21 consecutive
days signif icantly decreased immobil i ty by 27%
[t(14) = 3.864, p < 0.01], increased swimming by 133%
[t(14) = 4.604 ns], and had no influence on climbing behavior
[t(14) = 0.483, ns] (Fig. 3c).
The influence of studied compounds or fluoxetine
on locomotor activity of mice after chronic treatment
Neither HBK-14 (1.25 and 2.5 mg/kg) [F(2,21) = 0.038, ns],
HBK-15 (0.3, 0.625 and 1.25mg/kg) [F(3,28) = 0.588, ns] nor
fluoxetine (10 mg/kg) [t(14) = 0.436, ns] influenced locomo-
tor activity in mice (Table 1).
The influence of studied compounds on serotonin levels
in murine hippocampi after acute and chronic treatment
Acute treatment with the studied compounds showed no effect
on the hippocampal serotonin levels (Fig. 4a). Administration
of HBK-14 (2.5 mg/kg) and HBK-15 (0.625 and 1.25 mg/kg)
for 21 days significantly increased serotonin levels in murine
hippocampi by 25%, 46% and 48%, respectively (Fig. 4b).
The influence on the guinea-pig ileum contraction induced
by carbachol
Carbachol induced concentration-dependent guinea-pig ileum
contractions; the pEC50 value (negative logarithm of the ago-
nist concentration at which the response reached 50% of the
maximal response) was 7.09 ± 0.05 (Fig. 5). Neither HBK-14
nor HBK-15 administered alone induced ileal contractions
(data not shown). HBK-14 (1 and 3 μM) did not inhibit
carbachol-induced contractions (Fig. 5a); however, at the con-
centration 10 μM it decreased the maximum effect of carba-
chol by 25%, which suggested a non-competitive antagonism.
550 Metab Brain Dis (2017) 32:547–556
HBK-15 (1 μM) slightly shifted the carbachol response to the
right without decreasing themaximal response, which indicated
a competitive interaction with muscarinic receptors. The affin-
ity expressed as the pKB was 6.01 ± 0.01. Higher concentra-
tions of HBK-15 (3 and 10 μM) decreased the maximum effect
of carbachol by 21% and 65%, respectively (Fig. 5b). This
suggested a non-competitive type of antagonism.
The effect of studied compounds on learning and memory
in the step-through passive avoidance task in mice
Evaluation of cognitive-enhancing properties in naïve mice
In the acquisition trial of the passive avoidance task, none
of the compounds affected latency times [HBK-14:
F(2,27) = 0.393, ns; HBK-15: F(3,31) = 0.377, ns; fluox-
etine: F(3,36) = 0.282, ns] (Fig. 6a). However, in reten-
tion trial HBK-15 (0.625 mg/kg) significantly increased
latency time [F(3,31) = 3.564, p < 0.05] (Fig. 5a). In
contrast, neither HBK-14 (1.25 and 2.5 mg/kg) nor fluox-
etine (5, 10 and 20 mg/kg) influenced latencies in reten-
tion trial [F(2,27) = 0.305, ns and F(3,36) = 0.0.96, ns,
respectively] (Fig. 6a).
The effect on scopolamine-induced cognitive dysfunction
In the acquisition trial, neither the studied compounds
[ H BK - 1 4 : F ( 3 , 3 6 ) = 2 . 4 4 6 , n s , H BK - 1 5 :
F(4,45) = 2.030, ns] nor fluoxetine [F(4,45) = 2.197, ns]
affected latency times; however we observed significant
Fig. 3 Antidepressant-like effect
of HBK-14, HBK-15 and fluoxe-
tine after chronic treatment in
mice. HBK-14, HBK-15, fluoxe-
tine or saline were administered
intraperitoneally to mice for 21
consecutive days. 24 h after the
last injection the forced swim test
was performed. Control groups
received 0.9% NaCl (saline).
Statistical analysis: one-way
ANOVA (Newman-Keuls post
hoc) when three or more groups
were compared or Student t-test if
two groups were compared,
*p < 0.05, **p < 0.01,
***p < 0.001 vs respective saline-
treated group; n = 8 mice per
group
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differences in the retention trial (Fig. 6b). Scopolamine
(1 mg/kg) compared with control (saline) significantly
reduced latency times, and this effect was reversed by
HBK-15 (0.625 mg/kg) [F(4,45) = 29.22, p < 0.0001]
but not HBK-14 (1.25 and 2.25) [F(3,36) = 53.71,
p < 0.0001] or fluoxetine (5, 10 and 20 mg/kg)
[F(4,45) = 58.86, p < 0.0001](Fig. 6b).
Discussion
In the present study we found that dual 5-HT1A and 5-HT7
antagonists i .e . HBK-14 and HBK-15 possessed
antidepressant-like activity and increased serotonin levels in
the hippocampus after chronic treatment. HBK-15 possessed
very weak cholinolytic properties, whereas HBK-14 did not
block muscarinic receptors. Moreover, acute administration of
HBK-15 enhanced memory of mice and significantly amelio-
rated memory impairment caused by scopolamine.
Although the data are inconsistent some studies show that
5-HT1A and 5-HT7 receptor blockade might have potential in
the treatment of major depressive disorder (reviewed in Pytka
et al. 2016c). Researchers proved that 5-HT1A receptor defi-
cient mice were less immobile in the forced swim test than
wild-type control (Parks et al. 1998; Heisler et al. 1998). This
suggests that the lack of functional 5-HT1A receptors favors a
less depressed phenotype. Similarly, deletion of 5-HT7 gene
(Guscott et al. 2005) as well as 5-HT7 receptor antagonists
(Wesołowska et al. 2006) resulted in antidepressant-like effect
in various animal tests. Altogether, these findings indicate that
5-HT1A and 5-HT7 receptor antagonists may have potential as
antidepressants.
Our previous studies revealed that dual 5-HT1A and 5-HT7
receptor antagonists i.e. HBK-14 and HBK-15 possessed sig-
nificant antidepressant-like properties after acute treatment
(Waszkielewicz et al. 2015; Pytka et al. 2015a). Both com-
pounds showed α1-adrenolytic properties, and only HBK-15
did not lower blood pressure at antidepressant-like doses after
Table 1 HBK-14, HBK-15 and fluoxetine did not influence locomotor
activity of mice
Treatment Dose (mg/kg) Number of crossings ± S.E. M
Saline - 397.6 ± 72.9
HBK-14 1.25 394.4 ± 45.2
2.5 415.5 ± 53.6
Saline - 424.5 ± 61.5
HBK-15 0.3 363.3 ± 65.4
0.625 472.0 ± 47.8
1.25 442.0 ± 63.7
Saline - 430.6 ± 34.9
Fluoxetine 10 405.5 ± 45.9
HBK-14, HBK-15, fluoxetine or saline were administered intraperitone-
ally to mice for 21 consecutive days. The locomotor activity was recorded
individually for each animal in activity cages between the 2nd and the 6th
min (i.e., the time equal to the observation period in the forced swim test).
Control groups received 0.9% NaCl (saline) Statistical analysis: one-way
ANOVA (Newman-Keuls post hoc) when three or more groups were
compared or Student’s t-test if two groups were compared; n=8 mice
per group
Fig. 4 The influence on
serotonin levels in murine
hippocampi after acute (Panel a)
or chronic (Panel b) treatment
with HBK-14 or HBK-15. HBK-
14, HBK-15 or saline were ad-
ministered intraperitoneally to
mice 30 min (Panel a) or for 21
consecutive days (Panel b) before
tissue collection. Control groups
received 0.9% NaCl (saline).
Statistical analysis: one-way
ANOVA (Newman-Keuls post
hoc), *p < 0.05, **p < 0.01 vs
respective saline-treated group;
n = 6 mice per group
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single administration (Pytka et al. 2016b). Interestingly, none
of the compounds affected blood pressure after chronic admin-
istration (Pytka et al. 2016d). Here, we evaluated antidepressant-
like activity of HBK-14 and HBK-15 after chronic administra-
tion in mice. Both compounds injected for 21 days showed
antidepressant-like activities in the mouse forced swim test.
None of them affected locomotor activity of mice; therefore,
the observed effects were specific. Both compounds increased
swimming, whereas had no influence on climbing behaviors.
Since serotonin-targeting antidepressants increase swimming be-
havior in rodents (Nakatomi et al. 2008), we concluded that the
serotonergic system was involved in the antidepressant-like ef-
fect of the studied compounds. HBK-15 showed stronger
antidepressant-like properties than HBK-14, which is in agree-
ment with our previous findings (Pytka et al. 2015a).
Interestingly, HBK-15 administered chronically showed
antidepressant-like properties at lower dose (0.625 mg/kg) than
the dose active after acute treatment (1.25 mg/kg) (Pytka et al.
2015a). This is a common phenomenon for antidepressants,
since antidepressant effect requires adaptive changes at the neu-
ronal receptor level. Similarly, fluoxetine (Contreras et al. 2001)
or Hypericum perforatum (Lozanondash and Rodriguez-L
2010) administered chronically showed antidepressant-like ef-
fects at lower doses than those active after acute injection.
According to the serotonin hypothesis a deficit in brain
serotonergic activity might be a cause of depression or an
important vulnerability factor in this disease. The findings
are divergent, but some studies reported a decrease in seroto-
nin or its metabolite levels in the brains of suicide victims or
suicide attempters (for review, see Mann et al. 1989). The
reduced levels of serotonin were most frequently found in
brainstem. Although there are many other theories, the sero-
tonin hypothesis is still to date, as most antidepressants in
clinical use enhance the serotonergic neurotransmission.
Since many antidepressants elevate serotonin levels, we
investigated the influence of studied compounds on the level
Fig. 5 The effect of HBK-14 and HBK-15 on muscarinic receptor in
isolated guinea-pig ileum. Concentration–response curves to carbachol
in the absence or presence of increasing concentrations of HBK-14 or
HBK-15. The results are expressed as the percentage of maximal re-
sponse to carbachol in the corresponding concentration–response curve.
Each point represents the mean ± S.E. M (n = 4–8)
Fig. 6 The effect of studied compounds or fluoxetine on learning and
memory in the mouse step-through passive avoidance task. HBK-14,
HBK-15, fluoxetine or saline and/or scopolamine were administered in-
traperitoneally to mice 30 min before the acquisition trial of the step-
through passive avoidance test. The compounds were injected alone
(Panel a) or jointly with scopolamine (Panel b). Control groups received
0.9% NaCl (saline). Statistical analysis: one-way ANOVA (Turkey post
hoc), *p < 0.05, ****p < 0.0001 vs respective saline-treated group,
#p < 0.05 vs respective saline + scopolamine-treated group n = 8–10mice
per group
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of serotonin in the hippocampus after acute and chronic treat-
ment. Scientists proved that hippocampus plays a central role
in major depression (for review see: Campbell and Macqueen
2004). Our experiments showed that chronic (but not acute)
treatment with the studied compounds caused a significant
increase in the level of hippocampal serotonin. In both cases
the increase in serotonin levels was in parallel with a decrease
in the immobility of mice in the forced swim test. Since hip-
pocampus plays crucial role in mood disorders and reduced
serotonin levels might occur in depression, we believe that the
fact that the studied compounds elevate hippocampal seroto-
nin levels might be beneficial in depressed individuals.
Cognitive dysfunction is very common among patients
with major depressive disorder and significantly affects
their capacity to function (Darcet et al. 2016). Carvalho
et al. (2015) suggested that several factors might contrib-
ute to cognitive dysfunction in major depressive disorder
i.e. hyperactive hypothalamic-pituitary-adrenal axis, an
increase in oxidative and nitrosative stress, increased ap-
optosis or diminished neurotrophic support. The cognitive
impairments mostly occur during depressive episodes and
include deficits in executive functions (attention, process-
ing speed, cognitive flexibility) or learning and memory.
Bearing that in mind, in the second part of our studies, we
examined the influence of dual 5-HT1A and 5-HT7 antagonists
on learning and memory in mice after acute administration.
Since the blockade of muscarinic receptors may cause various
unfavorable effects such as memory impairment, we first in-
vestigated potential cholinolityc properties of the studied com-
pounds. Our experiments revealed that HBK-14 possessed no,
and HBK-15 very weak and negligible cholinolytic activity.
Both compounds reduced carbachol maxima at the concentra-
tion of 10 μM, which suggested a non-specific or additional
site of interaction (most likely not related to muscarinic recep-
tors). In comparison, previous experiments performed in our
laboratory showed that pA2 value for atropine (cholinolytic
drug) was 8.985 (Mogilski et al. 2015), which was a much
higher value than pKB (5.99) obtained for HBK-15.
The data on the effects of 5-HT1A and 5-HT7 receptor li-
gands on learning and memory in rodents are ambiguous.
Galeotti et al. (2000) as well as Tsuji et al. (2002) proved that
stimulating 5-HT1A receptor in mice promoted learning and
memory. Opposite results presented Madjid et al. (2006), who
reported that 5-HT1A antagonists facilitated aversive learning
in mice. Interestingly, the Authors also showed that 8-OH-
DPAT (5-HT1A agonist) displayed biphasic effect on retention
times. Similarly, studies on the role of 5-HT7 receptor in cog-
nitive function are also conflicting (reviewed in Meneses
2014). Nevertheless, 5-HT7
−/− mice showed impaired contex-
tual hippocampal-dependent learning and decreased long-
term synaptic plasticity in the hippocampus (Roberts et al.
2004). Moreover, both genetic and pharmacological inactiva-
tion of 5-HT7 receptor in mice resulted in deficits in
hippocampus-associated spatial memory in the location rec-
ognition test (Sarkisyan and Hedlund 2009).
In the present study, we determined the influence of both
dual 5HT1A and 5-HT7 antagonists on learning and memory
using the step-through passive avoidance test, which is a
hippocampus-dependent memory task. In this test animals
need to inhibit their natural tendency to enter the dark cham-
ber. We showed that only HBK-15 administered alone pos-
sessed memory-enhancing properties in passive avoidance
task. Moreover, the compound ameliorated memory deficits
induced by scopolamine in this test. HBK-14 and fluoxetine
were inactive in the step-through passive avoidance task.
Interestingly, in both experiments HBK-15 displayed an
inverted U-shaped dose-effect curve (0.625 mg/kg). This non-
linear relationship was frequently reported in pharmacological
studies on cognitive functions and memory (Baldi and
Bucherelli 2005). Although an inverted U-shaped dose-ef-
fect is widely described, it is very poorly understood.
Scientists proposed several theories (e.g. arousal hypoth-
esis), but the effect is most likely multifactorial and there-
fore difficult to explain.
Studies suggested that 5-HT7 receptor blockade resulted in
the cognitive deficits in mice (Sarkisyan and Hedlund 2009;
Freret et al. 2014). Eriksson et al. (2008) showed that even
though SB-269970 (administered alone before the training
session) had no effect on retention latency, it enhanced
amnestic effects of 8-OH-DPAT in the passive avoidance test
in mice. Since 8-OH-DPAT is also 5-HT7 receptor agonist, the
Authors concluded that 5-HT7 receptor stimulation by 8-OH-
DPAT counteracts 5-HT1A receptor-mediated impairments in
hippocampal-dependent contextual learning. Our findings are
in agreement with the above studies, since our previous ex-
periments revealed that HBK-15 compared with HBK-14
showed around three-fold stronger antagonistic properties at
5-HT1A and weaker at 5-HT7 receptor (Pytka et al. 2015a).We
believe that these slight differences in HBK-14 and HBK-15
receptor profiles might be responsible for the observed differ-
ences in the activity in passive avoidance task.
The limitation of our study was the fact that antidepressant-
like activity of the compounds was not tested using animal
model of depression (e.g. chronic unpredictable mild stress).
Since depression is closely associated with stress, this would
provide more insight into the therapeutic potential of studied
compounds. Furthermore, we should also confirm memory-
enhancing activity of HBK-15 using other tests, such as
Morris water maze or Y-maze, as well as after chronic
treatment.
Therefore, in future studies we plan to examine
antidepressant-like properties of both compounds utilizing
animal models of depression. We also intend to evaluate
the influence of acute and repeated administration of
HBK-15 on learning and memory using other behavioral
paradigms in rodents.
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Conclusion
We demonstrated that both dual 5-HT1A and 5-HT7 receptor
antagonists (i .e. HBK-14 and HBK-15) possessed
antidepressant-like activity and increased serotonin levels in
the hippocampus after chronic treatment. None of the com-
pounds displayed strong cholinolytic properties. Moreover,
HBK-15 showed memory-enhancing activity and ameliorated
memory impairment caused by scopolamine after acute ad-
ministration. We think that dual 5-HT1A and 5-HT7 antago-
nists might have potential in the treatment of depressive dis-
orders with cognitive dysfunction, and therefore require ex-
tended studies to explore their pharmacological profile.
Acknowledgments We wish to thank Agnieszka Niedbał and Teresa
Dobrut for their technical assistance. This study was supported by
Jagiellonian University grant number K/DSC/001955.
Compliance with ethical standards
Ethical approval All applicable international, national, and/or institu-
tional guidelines for the care and use of animals were followed. All
procedures performed in studies involving animals were in accordance
with the ethical standards of the institution or practice at which the studies
were conducted.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Arunlakshana O, Schild HO (1959) Some quantitative uses of drug an-
tagonists. Br J Pharmacol Chemother 14:48–58. doi:10.1111/j.1476-
5381.1959.tb00928.x
Baldi E, Bucherelli C (2005) The inverted Bu-shaped^ dose-effect rela-
tionships in learning and memory: modulation of arousal and con-
solidation. Nonlinearity Biol Toxicol Med 3:9–21. doi:10.2201
/nonlin.003.01.002
Biringer E, Rongve A, Lund A (2009) A review of modern antidepres-
sants effects on neurocognitive function. CPSR 5:164–174.
doi:10.2174/157340009788971137
Borsini F (1995) Role of the serotonergic system in the forced swimming
test. Neurosci Biobehav Rev 19:377–395
Campbell S, Macqueen G (2004) The role of the hippocampus in the
pathophysiology of major depression. J Psychiatry Neurosci 29:
417–426
Carvalho A, Miskowiak K, Hyphantis T et al (2015) Cognitive dys-
function in depression – pathophysiology and novel targets.
CNS Neurol Disord Drug Targets 13:1819–1835. doi:10.2174
/1871527313666141130203627
Contreras CM, Rodriguez-Landa JF, Gutiérrez-García AG, Bernal-
Morales B (2001) The lowest effective dose of fluoxetine in the
forced swim test significantly affects the firing rate of lateral septal
nucleus neurones in the rat. J Psychopharmacol 15:231–236
Darcet F, Gardier AM, Gaillard R et al (2016) Cognitive dysfunction in
major depressive disorder. A Translational Review in Animal
Models of the Disease. Pharmaceuticals. doi:10.3390/ph9010009
Eriksson TM, Golkar A, Ekström JC et al (2008) 5-HT7 receptor stimu-
lation by 8-OH-DPAT counteracts the impairing effect of 5-HT1A
receptor stimulation on contextual learning inmice. Eur J Pharmacol
596:107–110. doi:10.1016/j.ejphar.2008.08.026
Freret T, Paizanis E, Beaudet G et al (2014) Modulation of 5-HT7 recep-
tor: effect on object recognition performances in mice.
Psychopharmacology 231:393–400. doi:10.1007/s00213-013-
3247-x
Galeotti N, Ghelardini C, Bartolini A (2000) Role of 5-HT1A receptors in
a mouse passive avoidance paradigm. Jpn J Pharmacol 84:418–424
Glikmann-Johnston Y, Saling MM, Reutens DC, Stout JC (2015)
Hippocampal 5-HT1A receptor and spatial learning and memory.
Front Pharmacol 6:289. doi:10.3389/fphar.2015.00289
Guscott M, Bristow LJ, Hadingham K et al (2005) Genetic knockout and
pharmacological blockade studies of the 5-HT7 receptor suggest
therapeutic potential in depression. Neuropharmacology 48:492–
502. doi:10.1016/j.neuropharm.2004.11.015
Heisler LK, Chu HM, Brennan TJ et al (1998) Elevated anxiety and
antidepressant-like responses in serotonin 5-HT1A receptor mutant
mice. Proc Natl Acad Sci U S A 95:15049–15054
Lee HE, Jeon SJ, Ryu B et al (2016) Swertisin, a C-glucosylflavone,
ameliorates scopolamine-induced memory impairment in mice with
its adenosine A1 receptor antagonistic property. Behav Brain Res
306:137–145. doi:10.1016/j.bbr.2016.03.030
Lozanondash R, Rodriguez-L JF (2010) Antidepressant-like effects of
two commercially available products of Hypericum perforatum in
the forced swim test: a long-term study. J Med Plant Res 4:131–137
Madjid N, Tottie EE, Lüttgen M et al (2006) 5-Hydroxytryptamine 1A
receptor blockade facilitates aversive learning in mice: interactions
with cholinergic and glutamatergic mechanisms. J Pharmacol Exp
Ther 316:581–591. doi:10.1124/jpet.105.092262
Mann JJ, Arango V, Marzuk PM et al (1989) Evidence for the 5-HT
hypothesis of suicide. A review of post-mortem studies. Br J
Psychiatry Suppl 8:7–14
McIntyre RS, Harrison J, Loft H et al (2016) The effects of vortioxetine
on cognitive function in patients with major depressive disorder
(MDD): a meta-analysis of three randomized controlled trials. Int J
Neuropsychopharm . doi:10.1093/ijnp/pyw055pyw055
Meneses A (2014) Memory formation and memory alterations: 5-HT6
and 5-HT7 receptors, novel alternative. Rev Neurosci 25:325–356.
doi:10.1515/revneuro-2014-0001
Mogilski S, Kubacka M, Redzicka A et al (2015) Antinociceptive, anti-
inflammatory and smooth muscle relaxant activities of the
pyrrolo[3,4-d]pyridazinone derivatives: possible mechanisms of ac-
tion. Pharmacol Biochem Behav 133:99–110. doi:10.1016/j.
pbb.2015.03.019
Nakatomi Y, Yokoyama C, Kinoshita S et al (2008) Serotonergic media-
tion of the antidepressant-like effect of the green leaves odor inmice.
Neurosci Lett 436:167–170. doi:10.1016/j.neulet.2008.03.013
Parks CL, Robinson PS, Sibille E et al (1998) Increased anxiety of mice
lacking the serotonin1A receptor. Proc Natl Acad Sci U S A 95:
10734–10739
Pytka K, Partyka A, Jastrzębska-Więsek M et al (2015a) Antidepressant-
and anxiolytic-like effects of new dual 5-HT1A and 5-HT7 antago-
nists in animal models. PLoS One 10:e0142499. doi:10.1371
/journal.pone.0142499
PytkaK, RapaczA, ZygmuntM et al (2015b) Antidepressant-like activity
of a new piperazine derivative of xanthone in the forced swim test in
mice: the involvement of serotonergic system. Pharmacol Rep 67:
160–165. doi:10.1016/j.pharep.2014.08.016
Pytka K, Walczak M, Kij A et al (2015c) The antidepressant-like activity
of 6-methoxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-
9-one involves serotonergic 5-HT1A and 5-HT2A/C receptors
Metab Brain Dis (2017) 32:547–556 555
activation. Eur J Pharmacol 764:537–546. doi:10.1016/j.
ejphar.2015.07.041
Pytka K, Kazek G, Siwek A et al (2016a) HBK-7 — a new xanthone
derivative and a 5-HT1A receptor antagonist with antidepressant-
like properties. Pharmacol Biochem Behav 146-147:35–43.
doi:10.1016/j.pbb.2016.04.005
Pytka K, Lustyk K, Żmudzka E et al (2016b) Chemically homoge-
nous compounds with antagonistic properties at all α1-
adrenoceptor subtypes but not β1-adrenoceptor attenuate
adrenaline-induced arrhythmia in rats. Front Pharmacol 7:48.
doi:10.3389/fphar.2016.00229
Pytka K, Podkowa K, Rapacz A et al (2016c) The role of serotoner-
gic, adrenergic and dopaminergic receptors in antidepressant-
like effect. Pharmacol Rep 68:263–274. doi:10.1016/j.
pharep.2015.08.007
Pytka K, Głuch-Lutwin M, Knutelska J et al (2016d) HBK-14 and HBK-
15 do not influence blood pressure, lipid profile, glucose level, or
liver enzymes activity after chronic treatment in rats. PLoS ONE 11:
e0165495. doi:10.1371/journal.pone.0165495
Roberts AJ, Krucker T, LevyCL et al (2004)Mice lacking 5-HT receptors
show specific impairments in contextual learning. Eur J Neurosci
19:1913–1922. doi:10.1111/j.1460-9568.2004.03288.x
Sarkisyan G, Hedlund PB (2009) The 5-HT7 receptor is involved in
allocentric spatial memory information processing. Behav Brain
Res 202:26–31. doi:10.1016/j.bbr.2009.03.011
Stiedl O, Pappa E, Konradsson-Geuken Å, Ögren SO (2015) The role of
the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interac-
tion in emotional learning and memory. Front Pharmacol 6:259–
217. doi: 10.3389/fphar.2015.00162
TanakaM, Telegdy G (2008) Involvement of adrenergic and serotonergic
receptors in antidepressant-like effect of urocortin 3 in a modified
forced swimming test in mice. Brain Res Bull 77:301–305.
doi:10.1016/j.brainresbull.2008.08.012
Tsuji M, Takeda H, Matsumiya T (2002) Modulation of passive avoid-
ance in mice by the 5-HT1A receptor agonist Flesinoxan: compar-
ison with the benzodiazepine receptor agonist diazepam.
Neuropsychopharmacology 28:664–674. doi:10.1038/sj.
npp.1300080
Waszkielewicz AM, Pytka K, Rapacz A et al (2015) Synthesis and eval-
uation of antidepressant-like activity of some 4-substituted 1-(2-
methoxyphenyl)piperazine derivatives. Chem Biol Drug Des 85:
326–335. doi:10.1111/cbdd.12394
Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E (2006)
Effect of the selective 5-HT7 receptor antagonist SB 269970 in
animal models of anxiety and depression. Neuropharmacology 51:
578–586. doi:10.1016/j.neuropharm.2006.04.017
556 Metab Brain Dis (2017) 32:547–556
